AIATELLA’s AI technology has already been applied to identify multiple cases of potentially life-threatening cardiovascular disease, which otherwise may not have been found until it was too late. The fresh funds will help the company secure clinical certification for their tools to help doctors make more efficient diagnoses and to launch a preventative screening technology that can be used anywhere, at any time.

Helsinki, Finland (June 4th, 2025) Finnish medtech startup AIATELLA has secured €2 million in funding to accelerate the development and scaling of its AI-powered cardiovascular imaging technology. The funding will help the company conduct clinical trials and develop its ultrasound-based preventative screening, which detects and quantifies carotid artery narrowing in minutes. The round was led by Helsinki-based Nordic Science Investments, with Specialist VC, Harjavalta Ventures, Business Finland, and a syndicate of angel investors also joining the round.

AIATELLA’s multi-modal Automated Image Measurement (AIM) technology uses images from prevalent technologies like MRI, CT, and ultrasound to analyse vascular imaging, not only detecting, but quantifying abnormalities and changes over time in at-risk patients. With this technology, specialists no longer need to spend up to an hour manually measuring images and documenting changes. Automated analysis makes these tasks take minutes, allowing clinicians to focus more on patient care. The company is currently in medical approval processes in several countries across Europe and North America, including the UK, France, and the United States.

“When I was in medical education in the UK, my mentor told me that you can save thousands of lives in the operating room, but if you want to save millions, that happens in society. I saw that the current imaging workflows take a lot of time and resources, with ever-increasing scan volumes and a global shortage of radiologists leading to large backlogs; Radiologists were, and are, burning out. Our technology helps medical professionals analyse imaging much more efficiently, and at an earlier stage, so patients can get help before it’s too late,” says Jack Parker, Co-Founder and CEO at AIATELLA.

AIATELLA’s technology has firstly been applied to the aorta, the largest artery in the body, but the company’s vision is to expand their coverage to every blood vessel in the body. 

"AIATELLA's solutions have the potential to streamline our workflow by automating measurements in cardiovascular imaging, saving clinicians significant time per scan, and allowing us to focus our attention on interpretation. The scalability of this technology means we can provide standardised expert-level measurements regardless of the degree of expertise of the reporter. I am excited about the impact this could have for the NHS in terms of workflow optimisation and equitable patient care," says Anna Beattie, Consultant Cardiothoracic Radiologist, Radiology Research and AI Lead at Newcastle Hospitals NHS Foundation Trust.

The lead investor, Nordic Science Investments, which supports university research teams turning their groundbreaking inventions into commercial success stories, was particularly drawn to AIATELLA’s unique combination of cutting-edge technology, clinical insight, and a clear path to impact.

"AIATELLA is tackling one of the most significant opportunities in medicine: using AI to transform radiology. The company is perfectly positioned to lead the shift from reactive to preventative cardiovascular care and to replace outdated, manual workflows with intelligent, automated diagnostics.,” says Alexandra Gylfe, Partner at Nordic Science Investments.

Preventative cardiovascular screening at scale

In addition to AIM for medical professionals, the company is also developing an ultrasound-based portable screening technology, enabling mass screening of people before symptoms appear. Cardiovascular diseases are the leading cause of death globally, but up to 80% of these deaths are preventable through early detection and treatment. However, patients often do not enter the healthcare system until it’s too late and they experience severe symptoms, such as a stroke or a heart attack.

With its portable screening technology, AIATELLA aims to make early cardiovascular disease detection a routine part of regular health checkups, whether for occupational health, insurance assessments, or integrated with other healthcare initiatives like mobile blood banks, vaccination drives, or disease prevention programs. By enabling screening in diverse settings, the technology helps remove barriers to early diagnosis and supports broader access to preventative cardiovascular care. 

"AIATELLA’s preventative screening services have a clear and powerful mission: to bring early detection of cardiovascular problems to millions of people in a cost-effective way. We are confident in the potential of accessible preventative technology, especially in today’s world of overburdened healthcare systems," says Kaspar Hanni, Partner at Specialist VC.

The portable screening technology has already been used in partnership with medical professionals at screening events in Finland and the UK, and helped identify tens of individuals potentially at risk, who were then referred to healthcare professionals for further evaluation. With screening at scale, the company also aims to gain essential insights into differences in how cardiovascular diseases present and progress between different ethnicities and sexes, as symptoms often present differently between people. Acknowledging and working to close the gender and ethnicity health gap is a key priority for AIATELLA.

AIATELLA

AIATELLA is on a mission to revolutionise radiology by automating the slow, manual processes involved in medical imaging. Founded in Helsinki, Finland, in 2022, the company’s technology makes image analysis 100 times faster than today, enhancing speed, accuracy, and consistency. AIATELLA empowers doctors to focus more on patient care, paving the way for truly preventative and personalised medicine for everyone.